Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Relay Therapeutics ( (RLAY) ) just unveiled an announcement.
On November 4, 2025, Relay Therapeutics expanded its Board of Directors by appointing Lonnel Coats and Habib Dable, both former biotech CEOs with significant commercialization expertise. This strategic move aligns with the company’s ongoing efforts to advance its clinical programs, particularly the RLY-2608 trials in breast cancer and vascular malformations. Additionally, Relay reported its third quarter 2025 financial results, highlighting a net loss reduction compared to the previous year and a strong cash position of $596 million, expected to support operations into 2029.
The most recent analyst rating on (RLAY) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The overall stock score for Relay Therapeutics is primarily influenced by its financial performance and technical analysis. While the company maintains a stable balance sheet, significant losses and cash flow challenges weigh heavily on its financial performance score. Technical analysis provides a more positive outlook with bullish momentum indicators. However, the poor valuation due to negative earnings and lack of dividends further impacts the overall score.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company focused on developing therapies for cancer and genetic diseases. Utilizing its Dynamo® platform, Relay aims to address previously intractable protein targets with its lead asset, RLY-2608, a pan-mutant selective PI3Kα inhibitor currently in Phase 3 trials for metastatic breast cancer and vascular malformations.
Average Trading Volume: 1,698,517
Technical Sentiment Signal: Buy
Current Market Cap: $1.18B
See more data about RLAY stock on TipRanks’ Stock Analysis page.